Division of Bariatric and Foregut Surgery at 2780Geisinger Health System, Danville, PA, USA.
21599The Obesity Institute at Geisinger Health System, Danville, PA, USA.
Am Surg. 2022 Nov;88(11):2760-2767. doi: 10.1177/00031348221121551. Epub 2022 Sep 7.
Type 2 Diabetes Mellitus (T2DM) is highly prevalent comorbidity in patients with morbid obesity. It is still unclear whether a cutoff value of preoperative A1c represents an increased risk for major postoperative complications following Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG).
Retrospective MBSAQIP Participant Use File cohort for both years 2017 and 2018 were analyzed to evaluate the relationship between HbA1c in patients with morbid obesity and T2DM undergoing bariatric surgery, and the 30 days postoperative major complications by Clavien-Dindo classification (III/IV). We used an HbA1c cutoff of <7, > =7, and stratified by 1% increment for a total of 11 groups. We used univariate and multivariate logistic regression to analyze the outcome of the complications. Predicted probabilities were calculated for major complications. All statistical tests were two-sided with a -value of less than .05 considered as a cut-off for statistical significance.
Of 42,181 patients that met inclusion criteria, there were 20,955 identified with HbA1c <7%, and 21,226 patients with HbA1c >7%. Utilizing HbA1c <7% as a cutoff, we found no consistent statistical significance in the major postoperative complication in patients with HbA1c >7%, and when stratified with 1% increment between groups. We also found no significance between groups with risk adjustment.
Extensive analysis of the large MBSAQIP cohort didn't result in a clinically significant association between stratified HbA1c and 30-day Clavien-Dindo major complications (III/IV) following Roux-en-Y Gastric Bypass (RYGB) and (SG).
2 型糖尿病(T2DM)是病态肥胖患者的高发合并症。术前 A1c 的截断值是否代表 Roux-en-Y 胃旁路术(RYGB)和袖状胃切除术(SG)后主要术后并发症风险增加,目前仍不清楚。
分析了 2017 年和 2018 年 MBSAQIP 参与者使用文件队列的回顾性队列,以评估病态肥胖合并 T2DM 患者的 HbA1c 与接受减重手术的患者之间的关系,并根据 Clavien-Dindo 分类(III/IV)评估术后 30 天主要并发症。我们使用 HbA1c 截断值<7、≥7 和 1%递增分层,共 11 组。我们使用单变量和多变量逻辑回归分析并发症的结果。计算主要并发症的预测概率。所有统计检验均为双侧检验,以<.05 作为统计学显著性的界限。
在符合纳入标准的 42181 名患者中,有 20955 名患者的 HbA1c<7%,21226 名患者的 HbA1c>7%。当使用 HbA1c<7%作为截断值时,我们发现 HbA1c>7%的患者在主要术后并发症方面没有一致的统计学意义,并且当组间分层以 1%递增时也是如此。我们还发现,在风险调整后,组间也没有显著性差异。
对大型 MBSAQIP 队列的广泛分析并未导致 HbA1c 分层与 Roux-en-Y 胃旁路术(RYGB)和(SG)后 30 天 Clavien-Dindo 主要并发症(III/IV)之间存在临床显著相关性。